Hasil Pencarian - Gerald S. Falchook

  • Menampilkan 1 - 14 hasil dari 14
Perbaiki Hasil
  1. 1
    Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review

    Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review oleh Kavanya Feustel, Gerald S. Falchook

    Diterbitkan 2022-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    T cell Immunoglobulin and Mucin Domain Containing Protein 3 (TIM-3) Inhibitors in Oncology Clinical Trials: A Review

    T cell Immunoglobulin and Mucin Domain Containing Protein 3 (TIM-3) Inhibitors in Oncology Clinical Trials: A Review oleh Benjamin Duong, Pratyush Banskota, Gerald S. Falchook

    Diterbitkan 2024-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    B7-H3 Inhibitors in Oncology Clinical Trials: A Review

    B7-H3 Inhibitors in Oncology Clinical Trials: A Review oleh Kavanya Feustel, Jared Martin, Gerald S. Falchook

    Diterbitkan 2024-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers

    Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers oleh Martin V. Nguyen, Lydia Loof, Gerald S. Falchook

    Diterbitkan 2020-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Extracellular Signal-Regulated Kinase (ERK) Inhibitors in Oncology Clinical Trials

    Extracellular Signal-Regulated Kinase (ERK) Inhibitors in Oncology Clinical Trials oleh Haelee M Chin, David K Lai, Gerald S Falchook

    Diterbitkan 2019-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite‐stable metastatic colorectal cancer

    A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite‐stable metastatic colorectal cancer oleh Manish R. Patel, Gerald S. Falchook, Kensuke Hamada, Lukas Makris, Johanna C. Bendell

    Diterbitkan 2021-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810

    Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810 oleh Rom Leidner, Carlo Bifulco, Israel Lowy, Gerald S. Falchook, Elizabeth Stankevich, Brian Piening, Matthew G. Fury

    Diterbitkan 2016-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose

    Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose oleh Wenyuan Xiong, Manja Friese‐Hamim, Andreas Johne, Christopher Stroh, Manfred Klevesath, Gerald S. Falchook, David S. Hong, Pascal Girard, Samer El Bawab

    Diterbitkan 2021-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.

    PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. oleh Filip Janku, J Jack Lee, Apostolia M Tsimberidou, David S Hong, Aung Naing, Gerald S Falchook, Siqing Fu, Rajyalakshmi Luthra, Ignacio Garrido-Laguna, Razelle Kurzrock

    Diterbitkan 2011-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.

    KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. oleh Ignacio Garrido-Laguna, David S Hong, Filip Janku, Ly M Nguyen, Gerald S Falchook, Siqing Fu, Jenifer J Wheler, Rajyalakshmi Luthra, Aung Naing, Xuemei Wang, Razelle Kurzrock

    Diterbitkan 2012-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine

    Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine oleh Apostolia-Maria Tsimberidou, David S. Hong, Jennifer J. Wheler, Gerald S. Falchook, Filip Janku, Aung Naing, Siqing Fu, Sarina Piha-Paul, Carrie Cartwright, Russell R. Broaddus, Graciela M. Nogueras Gonzalez, Patrick Hwu, Razelle Kurzrock

    Diterbitkan 2019-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    736 A phase 1/2 open-label, dose-escalation study of ST-067, a decoy-resistant IL-18 cytokine, given as a monotherapy and with pembrolizumab in advanced solid tumor malignancies

    736 A phase 1/2 open-label, dose-escalation study of ST-067, a decoy-resistant IL-18 cytokine, given as a monotherapy and with pembrolizumab in advanced solid tumor malignancies oleh Mario Sznol, Harriet Kluger, Igor Puzanov, Gerald S Falchook, Ryan Sullivan, Matthew H Taylor, Justin C Moser, Aaron M Ring, Virginia E Paton, David Chonzi, Brage Garofalo, Mark Sonnemann, Hirdesh Uppal, Jeremy Barton, Beatrice Y McQueen

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    759 ADPORT-601 (TT-10–101): first-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in participants with selected advanced solid tumors

    759 ADPORT-601 (TT-10–101): first-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in participants with selected advanced solid tumors oleh Lawrence Fong, Sumit Subudhi, Gerald S Falchook, Russell Pachynski, Anthony El-Khoueiry, Ian Walters, Robert Krämer, Sushant Kumar, Kasim Mookhtiar, Justin Fairchild, Mohamad A Salkeni, Jaspreet Grewal, William Tester, Samik Upadhaya, Ana Rosa Saez Ibanez, Desa Rae Stanton-Pastore

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors

    Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors oleh Filip Janku, David S. Hong, Siqing Fu, Sarina A. Piha-Paul, Aung Naing, Gerald S. Falchook, Apostolia M. Tsimberidou, Vanda M. Stepanek, Stacy L. Moulder, J. Jack Lee, Rajyalakshmi Luthra, Ralph G. Zinner, Russell R. Broaddus, Jennifer J. Wheler, Razelle Kurzrock

    Diterbitkan 2014-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: